ESMO 2024: Latest in EGFR mutated NSCLC

Improved structure preservation with neo-adjuvant platinum-based chemo in patients with resectable NPNSCC

Retifanlimab plus chemo shows PFS benefit in recurrent or metastatic squamous cell carcinoma of the anal canal

TNBC: Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in OS compared to neoadjuvant chemo alone

Understanding the use of PARPi combinations to treat patients with mCRPC

Enzalutamide treatment boosted by Radium-223 in mCRPC

TACE combined with lenvatinib-pembrolizumab shows improved PFS in intermediate stage liver cancer

ESMO 2024: Optimising the personalisation of prostate cancer treatment

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies

Addition of relatlimab to nivolumab plus platinum-doublet chemo demonstrates improved clinical benefit in NSCLC

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer

NKT2152 demonstrates anti-tumor activity in heavily pretreated advanced clear cell RCC